EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Glycans on Tumor‐Derived Extracellular Vesicles for Cancer Liquid Biopsy: From Signatures to Selective Capture

Elisa S. Breet, Peter ten Dijke, Agustin Enciso‐Martinez

Small · 20.11.2026

DOI: 10.1002/smll.76699 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Small, online erschienen am 20.11.2026. Verfasst von Elisa S. Breet und 2 weiteren Autor:innen. Die Arbeit nennt 198 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: KWF Kankerbestrijding.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tumor‐derived extracellular vesicles (tdEVs) are stable carriers of tumor‐associated information in biofluids and have emerged as promising minimally invasive biomarkers for cancer detection and monitoring. While protein and nucleic acid cargo have been extensively characterized, the glycosylation landscape of tdEVs remains largely underexplored. Surface‐accessible glycans can be displayed across multiple glycoprotein and glycolipid scaffolds, potentially increasing targetable epitope density and enabling direct detection or enrichment of intact vesicles. Across cancer types, tumor‐associated EVs display recurrent glycan alterations, including altered fucosylation and sialylation, alongside cancer‐associated structures such as truncated O‐glycans, glycosphingolipids, and oncofetal chondroitin sulfate. These glycan alterations may reflect the malignant state of the cells from which the EVs originate, while certain EV‐associated glycans may also contribute to tumor progression. This review synthesizes current evidence on tdEV glycosylation across major glycan classes and critically evaluates the technical and biological challenges that limit clinical translation of EV‐associated glycans as cancer biomarkers. We propose a conceptual framework in which cancer‐enriched glycans are best exploited through structurally resolved multiplexed signatures, while cancer‐restricted glycans such as truncated O‐glycans and oncofetal chondroitin sulfate serve as tumor‐selective capture handles for downstream patient‐specific cargo profiling. Addressing methodological standardization and validation gaps will be essential to realize the potential of glycan‐based tdEV assays in precision oncology.

Förderung

  • KWF Kankerbestrijding

Zitieren

APA

Breet, E. S., Dijke, P. T., & Enciso‐Martinez, A. (2026). Glycans on Tumor‐Derived Extracellular Vesicles for Cancer Liquid Biopsy: From Signatures to Selective Capture. Small. https://doi.org/10.1002/smll.76699

Vancouver

Breet ES, Dijke PT, Enciso‐Martinez A. Glycans on Tumor‐Derived Extracellular Vesicles for Cancer Liquid Biopsy: From Signatures to Selective Capture. Small. 2026. doi:10.1002/smll.76699

BibTeX
@article{Breet2026,
  author = {Breet, Elisa S. and Dijke, Peter ten and Enciso‐Martinez, Agustin},
  title = {Glycans on Tumor‐Derived Extracellular Vesicles for Cancer Liquid Biopsy: From Signatures to Selective Capture},
  journal = {Small},
  year = {2026},
  doi = {10.1002/smll.76699}
}
Kostenlos starten →